

News Article downloaded from - <http://www.bioportfolio.com> on Wednesday, November 25, 2009

Read [Novartis drug Tasigna\(R\) meets primary endpoint in pivotal trial against Gleevec\(R\) as first-line treatment in chronic myeloid leukemia patients](#) on BioPortfolio.com

([http://www.bioportfolio.com/news/Novartis-drug-Tasigna\(R\)-meets-primary-endpoint.html](http://www.bioportfolio.com/news/Novartis-drug-Tasigna(R)-meets-primary-endpoint.html))

## **Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients**

**Tuesday 20th of October 2009 1:15**

12. Jabbour E, Cortes J, Kantarjian H, et al. Molecular Monitoring in Chronic Myeloid Leukemia Response to Tyrosine Kinase Inhibitors and Prognostic Implications. Cancer. DOI10.1002/cncr.23427. Published online 17 March 2008.

### Media Contacts

Media only:

Sabrina Oei

Novartis Oncology

P: +1 862 778 6387

Dana Kahn Cooper

P: +1 732 817 1800

C: +1 732 239 6664

Investors only:

Richard Jarvis

Novartis Corporation

P: +1 212 830 2433

SOURCE Novartis

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

